載入...
PITX3 promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients after radical prostatectomy
BACKGROUND: Molecular biomarkers that might help to distinguish between more aggressive and clinically insignificant prostate cancers (PCa) are still urgently needed. Aberrant DNA methylation as a common molecular alteration in PCa seems to be a promising source for such biomarkers. In this study, P...
Na minha lista:
| 發表在: | Clin Epigenetics |
|---|---|
| Main Authors: | , , , , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
BioMed Central
2016
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5037587/ https://ncbi.nlm.nih.gov/pubmed/27708722 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13148-016-0270-x |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|